A New Breakthrough in Targeted Therapy: Zolbetuximab Brings Hope to Patients with Advanced Gastric Cancer

In the global field of gastric cancer treatment, the development of Zolbetuximab marks a major milestone in targeted therapy. As the world’s first and only approved monoclonal antibody targeting Claudin 18.2, Zolbetuximab offers a new treatment option for selected patients with advanced gastric cancer. This innovative therapy is now available at Shanghai Jiahui International Hospital, bringing internationally aligned precision treatment to patients in China.

Claudin 18.2: A New Therapeutic Target for Gastric Cancer
Claudin 18.2 is an important member of the Claudin tight junction protein family. While its expression in healthy tissues is limited, it is highly expressed in several malignancies—particularly gastric cancer, pancreatic cancer, and esophageal cancer. This unique expression pattern makes it an ideal target for cancer treatment. Studies show that approximately 40%–60% of gastric cancer patients have medium to high Claudin 18.2 expression, making it especially valuable in HER2-negative patients. (1) Drugs targeting Claudin 18.2 bind specifically to tumor cells and activate immune-mediated killing, enabling precise treatment while minimizing damage to healthy tissues.

Precision Targeting with Significant Survival Benefits
Zolbetuximab has been approved in China, the United States, and Japan for first-line treatment of Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma.
Clinical studies show that the therapy significantly prolongs median overall survival (mOS) to 18.2 months, with the PPS population approaching 2 years. (2) Notably, subgroup analysis in the Chinese population demonstrated a 52% reduction in disease progression or death, offering even more substantial benefits for Asian patients. (3)

Shanghai Jiahui International Hospital: International-Standard Treatment, Fully Aligned with Global Advances
· Testing First: Claudin 18.2 testing is required before initiating therapy.
· One-Stop Oncology Care: After receiving test results, patients are encouraged to consult our specialists at Jiahui Cancer Center to discuss and tailor personalized treatment plans. Throughout the therapy, our clinicians closely monitor treatment response and safety.
· Multidisciplinary Medication Management: During the treatment process at Jiahui, clinical physicians, nurses, and pharmacists work together to monitor adverse reactions and comprehensively evaluate the patient’s condition, ensuring medication safety throughout the treatment journey.

If you or a family member meets the treatment criteria, please contact our customer service team for detailed consultation and a personalized treatment plan.

JICC Customer Service + Dr. Xue Peng Profile

(1) doi: 10.1056/NEJMc2409512
(2) Shitara et al. Lancet. 2023; 401(10389): 1655–1668
(3) Shitara K, et al. 2024 ASCO. Abstract 4036.